Close Menu

This story has been updated from a previous version to include comments made during Bio-Rad's earnings call.

NEW YORK (GenomeWeb) – Bio-Rad reported after the close of the market on Thursday that its second quarter revenues fell 2 percent on both a reported and currency-neutral basis.

For the three months ended June 30, Bio-Rad reported $504.7 million in net sales compared to $516.8 million in the year-ago quarter and short of analysts' average estimate of $515.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.